Board summary
Key figures
38,004
Registered population
62.7% aged 18–64
12.8%
Aged 65+
ICB 19.9% · England 17.9%
16.6%
Ethnic minority (non-White)
8.2% Asian · England 9.6%
25.3%
In IMD quintile 1
ICB 17.1% · England 21.0%
~9,084
Core20 residents (est.)
Resident basis; registered basis ~9,615 · see page 3
4,453
Hypertension register
+7.54% in 3 yrs · England +5.60%
349
SMI register
28.5% of Ashford's
608
COPD register
Reviews -1.77% in 3 yrs
Forecast to 2030
5,651
Hypertension patients, 2030
+1,198 on today
81.8%
QRISK ≥20% on statins, 2030
+8.32pp over 3 yrs
3.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Non-frail diabetes HbA1c control lags benchmarks.
Only 48.8% (922 of 1,888 patients) achieve HbA1c at or below 58 mmol/mol, below 56.0% in the ICB and 57.4% in England.
Annual asthma reviews trail borough and England.
Annual asthma review coverage is 60.4% (Ashford 63.3%, England 65.7%) after a -3.5% three-year change, leaving about 780 of 1,963 patients unreviewed.
Heart failure annual reviews exceed benchmarks.
Heart failure review completion reaches 86.8%, above Ashford (83.9%), the ICB (75.0%) and England (78.5%), following a +226.0% three-year change.
Population, age and ethnicity
Younger demographics and 7.0% projected growth may shape demand across 38,004 registered patients
Across 38,004 registered patients at Ashford Medical Partnership, the PCN has a younger demographic profile than benchmarks. Children aged 0-17 comprise 24.5% (9,305 patients), above Ashford (19.9%), NHS Kent and Medway ICB (20.7%) and England (19.6%). Conversely, 12.8% (4,880 patients) are aged 65+, below Ashford (20.9%), the ICB (19.9%) and England (17.9%). Projected population growth to 2030 is 7.0% (Ashford 6.4%, ICB 6.0%, England 2.3%; unverified methodology). Census area data indicates 83.4% White and 16.6% ethnic minorities (8.2% Asian), which reflect local resident composition rather than verified list ethnicity.
Age profile
65+: ICB 19.9%, England 17.9%
Ethnicity
Older people · falls rows are Ashford local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Ashford LA) | 1,562 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 81.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 48.8% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Ashford LA) | 748 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Ashford LA) | 18.8 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation affects 25.3% of patients, exceeding Ashford's 11.5% and England's 21.0%
Ashford Medical Partnership PCN has 25.3% of registered patients in the Core20 most deprived quintile, above Ashford (11.5%), NHS Kent and Medway ICB (17.1%) and England (21.0%), despite an average IMD decile of 5.0 (England 5.5). Across the single practice, this represents 9,615 patients, whereas resident LSOA estimates in deciles 1 and 2 sum to 9,084 (about 9,100: 2,532 aged 0-17, 5,550 aged 18-64, and 1,002 aged 65+), as these rest on different population bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
349
SMI register
0.93% recorded prevalence
183
Learning disability register
0.49% recorded prevalence
21
Care homes, 615 beds
In the PCN catchment
9.0%
Provide unpaid care
Ashford, Census 2021
The PCN records 349 patients on the severe mental illness register (0.9%) and 183 with learning disabilities (0.5%), alongside 21 catchment care homes with 615 beds. In Ashford borough, 9.0% of residents provide unpaid care and 12 people were recorded sleeping rough. Care home bed counts and local authority data describe area context rather than PCN patient utilisation.
Severe mental illness: physical health checks
On the 349-patient severe mental illness register (28.5% of Ashford's), blood pressure checks reached 75.4% (England 83.4%), while BMI recording reached 72.5% (England 82.1%) and alcohol recording 70.5% (England 81.8%). Routine physical health checks trail national benchmarks.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
4,453
Hypertension register
+7.54%
Register growth, 3 yrs
Ashford +3.83% · England +5.60%
+3.54pp
BP control, under 80
≤140/90 · +8.01pp aged 80+
+1,198
More patients by 2030
Forecast 5,651 (13.72%)
Hypertension case-finding and control
Hypertension prevalence is 11.9% (4,453 patients), below Ashford (16.0%), NHS Kent and Medway ICB (16.2%) and England (15.2%), yielding an unadjusted register gap of +1,335 to +1,637 patients that may reflect the younger population (12.8% aged 65+ vs 17.9% England). While 85.3% of patients have a recent blood pressure reading (Ashford 85.0%, England 90.0%), treatment to target reaches 62.3% (Ashford 64.0%, England 70.3%). Control among patients aged under 80 is 58.6%, lagging Ashford (60.2%) and England (67.8%). Lower blood pressure control than national benchmarks suggests that clinical titration and recall for registered under-80s could be prioritised alongside case-finding.
Lipids and statins
Statin treatment for patients with QRISK at or above 20% is 61.0% (Ashford 60.8%, England 63.6%), while CKD coverage is 65.9% (England 70.3%). Diabetes primary prevention statin prescribing reaches 75.2% (England 73.2%). Lower coverage in QRISK and CKD cohorts may highlight opportunities for targeted review.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 33,583 | £1.60 | £1.90 | £1.86 | £53,733 |
| Cardiovascular (all), 2025 | 48,640 | £5.36 | £3.57 | £3.33 | £260,710 |
Cardiovascular drugs cost £5.36 per item in 2025 (England £3.33), spending £98,739 more than at England's unit cost across 48,640 items. Lipid-modifying drugs cost £1.60 per item (England £1.82), spending £6,123 less across 27,834 items. Higher cardiovascular unit spend than England may reflect prescribing mix, which could be explored locally.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−3.52%
Asthma reviews, PCN 3-yr change
+4.44%
Asthma reviews, England
+2.29%
Asthma prevalence, PCN
Recorded COPD prevalence is 1.6% (608 patients) and fell 8.0% over three years (England +2.6%), while 79.3% of COPD patients had an annual review (England 76.4%). Asthma prevalence is 5.7% (1,963 patients), with 12-month reviews falling 3.5% over three years (England +4.4%) to 60.4% (England 65.7%), leaving about 780 patients unreviewed. Prescribing of asthma management items for ages 5-19 was 973 per 1,000 (England 1,488). Addressing annual asthma reviews is a key clinical care priority.
Cancer register and children's immunisation
The cancer register records 1,099 patients (2.9% prevalence vs England 3.8%). In Q1 2025/26, age-5 MMR1 coverage was 94.4%, but MMR2 fell to 88.0% (a 6.4 pp difference), and the 4-in-1 booster reached 81.6%, trailing the 95.0% target by 13.4 pp in a 125-child cohort.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.6%
Kent and Medway ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,630
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Kent and Medway ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 82.1% | 85.4% | 23% | 1,509 |
| Prostate | 54.4% | 53.2% | 37% | 1,435 |
| Lung | 29.4% | 33.8% | 21% | 1,109 |
| Bowel | 48.2% | 47.0% | 29% | 1,013 |
| Skin cancer | 87.5% | 87.8% | 23% | 562 |
In NHS Kent and Medway ICB, 55.6% of staged cancers (4,661 of 8,384) were diagnosed at stage 1 or 2 in 2022, slightly above England (55.3%) but 19.4 pp below the 75.0% national ambition by 2028. Staging completeness was 63.6% (8,384 of 13,189 registered cancers). In primary care, PCN cervical screening coverage (ages 25-49) fell 2.4% (England -1.0%) over 2023 to 2025 to 65.6%, below Ashford (69.7%) and England (66.8%). Breast screening coverage rose 15.2% (England +8.4%) to 71.7% (Ashford 75.8%, England 69.9%). ICB staging reflects wider system data rather than PCN performance. Trailing cervical screening coverage could delay early detection if non-attenders are not systematically recalled.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
At East Kent Hospitals University NHS Foundation Trust in July 2026 (provisional), 70.0% of cancer pathways met the 62-day standard, 15.0 pp below the 85.0% standard and trailing NHS Kent and Medway ICB (75.9%), England (71.2%) and Maidstone and Tunbridge Wells NHS Trust (87.4%), though above East Sussex Healthcare NHS Trust (67.0%). Faster diagnosis at 28 days reached 71.3%, 3.7 pp below the 75.0% standard and trailing England (79.3%). Waiting 6+ weeks for diagnostic tests was 48.4% (England 23.1%). Hospital waiting times describe provider performance rather than exclusive PCN referrals.
| Pathways within standard (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | Kent and Medway ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.28 | 84.20 | 81.78 | 76.78 | 79.32 |
| 31-day treatment (96%) | 96.67 | 98.19 | 98.35 | 95.84 | 92.50 |
| 62-day referral to treatment (85%) | 70.01 | 67.04 | 87.43 | 75.93 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Kent | East Sussex Healthcare | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 47.58 | 6.48 | 0.92 | 21.40 |
| CT | 37.45 | 0.48 | 0.51 | 9.92 |
| Echocardiography | 14.17 | 21.94 | 2.57 | 28.48 |
| Colonoscopy | 9.58 | 0.74 | 19.80 | 30.83 |
| Gastroscopy | 22.16 | 0.31 | 24.03 | 29.02 |
| All 15 DM01 tests | 48.38 | 5.27 | 6.42 | 23.14 |
| Community services activity | Kent residents | Kent and Medway ICB |
|---|---|---|
| Care contacts | 210,170 | 254,055 |
| Referrals | 59,360 | 68,085 |
| Patients with a contact | 60,605 | 72,060 |
Community services (residents of Kent), Jun 2026 (provisional). In June 2026 (provisional), 60,605 Kent residents had a community care contact across 210,170 contacts and 265,905 activities, while NHS Kent and Medway ICB recorded 72,060 patients and 254,055 contacts. Adults aged 65+ accounted for 65.8% of Kent contacts (138,250 of 210,170). These provisional counts reflect upper-tier authority and ICB activity rather than unique PCN patient utilization.
Practice variation and patient experience
Phone access lags England by 30.5 percentage points, while clinical QOF trails
Ashford Medical Partnership achieved 84.3% overall QOF achievement in 2025/26 (versus 92.5% England) and 84.7% in the clinical domain (versus 97.1%), while vaccination achievement reached 70.9% (versus 55.2%). Personalised care adjustments were 7.0% (versus 10.0% England). Lower clinical achievement may reflect chronic disease review gaps, though this has not been confirmed locally.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Ashford Medical | 158 | 25.3 | 26.4% | 70.5% | 66.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Non-frail diabetes control and asthma reviews trail England despite strong heart failure reviews
Over three years, relative review rates fell for asthma by 3.5% (England +4.4%) and COPD by 1.8% (England +2.8%), while non-frail diabetes HbA1c control fell 0.3% to 48.8% (England +4.4% to 57.4%; 922 of 1,888 patients). Conversely, heart failure reviews rose 226.0% (England +8.7%) to 86.8% (England 78.5%), and severe mental illness blood pressure checks rose 19.2 pp (England +4.4 pp). Prioritising routine review recall for diabetes and respiratory cohorts could recover ground lost relative to national trajectories.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD register
Asthma reviews
Depression register
Diabetes HbA1c control
COPD reviews
Heart failure reviews
BP check (SMI)
BP control, 80+
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Ashford | Asset | PCN | Ashford |
|---|---|---|---|---|---|
| Care homes (catchment) | 21 (615 beds) | n/a | Schools (catchment) | 62 | n/a |
| Children's centres | 3 | 6 | Places of worship | 25 | 99 |
| Libraries | 1 | 4 | Food banks (VCS) | 1 | 1 |
| Day centres (VCS) | 2 | 36 | Children and young people (VCS) | 1 | 23 |
| Carers support groups (VCS) | 2 | 15 | Primary schools (LA maintained) | 10 | 24 |
| Primary academies | 9 | 18 | Special schools | 1 | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured annual asthma review recall
Annual asthma reviews fell 3.5% over 2023 to 2025 to 60.4% (Ashford 63.3%, England 65.7%; England +4.4%), leaving about 780 of 1,963 registered patients unreviewed. For discussion: run structured asthma recall using a single review template, offering after-school or flexible slots and reviewing inhaler prescribing. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Under-80 hypertension titration and case-finding
Under-80s BP control is 58.6% (Ashford 60.2%, England 67.8%) and overall control is 62.3% (England 70.3%). Crude prevalence is 11.9% (4,453 of 38,004 vs 16.0% Ashford; unadjusted gap +1,335 to +1,637). For discussion: prioritise pharmacist-led titration recall for registered under-80s above 140/90 mmHg alongside searches for uncoded raised readings. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 3
Age-five pre-school booster recall
In Q1 2025/26 (125 five-year-olds), MMR1 reached 94.4% vs 88.0% for MMR2 (6.4 pp difference), while the 4-in-1 booster was 81.6% (ICB 82.6%, England 80.9%), 13.4 pp below the 95.0% target. For discussion: audit five-year-olds with MMR1 who missed MMR2 or the 4-in-1 booster, offering flexible clinic slots. Low cost, quick to run.
Evidence base: coverage against the 95% target is the direct measure of programme delivery and catch-up need; where coverage clusters low, that decides whether catch-up is organised at practice, PCN, school or outreach level.
Policy anchor: 10 Year Health Plan, shift from sickness to prevention.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Paediatric capacity and clinic planning (p2) | Aged 0-17 | Medium Term Planning Framework 2026 · Neighbourhood health framework | PCN |
| Core20 proactive review outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Severe mental illness physical checks (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension titration and recall review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall outreach (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephone access and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured annual asthma review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 2 · Under-80 hypertension titration and case-finding (p12) | Hypertension register · Hypertension: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Age-five pre-school booster recall (p12) | MMR dose 1 coverage at age 5 · MMR dose 2 coverage at age 5 · 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
